Paper10694631
Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock?
Evora PR. J Thorac Cardiovasc Surg, 2000. Cited by 37 papers, by iCite.
Cite this record
ConductScience Library. Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock? Papers, record 10694631. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/10694631
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock?
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anaphylaxis | Major topic |
| Cardiopulmonary Bypass | Major topic |
| Hypotension | Major topic |
| Methylene Blue | Major topic |
| Humans | |
| Vascular Resistance |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment on | 10384205 | Reversal of refractory hypotension with single-dose methylene blue after coronary artery bypass surgery. | https://conductscience.org/library/papers/10384205 |
Source PubMed
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 37 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36337249 | Methylene blue: a controversial diagnostic acid and medication? | Toxicol Res (Camb) | 2022 | https://conductscience.org/library/papers/36337249 | PubMed |
| 35274519 | Indigo Carmine Hemodynamic Studies to Treat Vasoplegia Induced by Compound 48/80 in a Swine Model of Anaphylaxis. | Braz J Cardiovasc Surg | 2022 | https://conductscience.org/library/papers/35274519 | PubMed |
| 31749797 | Refractory Anaphylaxis: Data From the European Anaphylaxis Registry. | Front Immunol | 2019 | https://conductscience.org/library/papers/31749797 | PubMed |
| 29657374 | Methylene Blue for Vasoplegic Syndrome Postcardiac Surgery. | Indian J Crit Care Med | 2018 | https://conductscience.org/library/papers/29657374 | PubMed |
| 25859872 | Twenty years of vasoplegic syndrome treatment in heart surgery. Methylene blue revised. | Rev Bras Cir Cardiovasc | 2015 | https://conductscience.org/library/papers/25859872 | PubMed |
| 24340007 | Methylene blue modulates transendothelial migration of peripheral blood cells. | PLoS One | 2013 | https://conductscience.org/library/papers/24340007 | PubMed |
| 22949982 | Effect of a single bolus of methylene blue prophylaxis on vasopressor and transfusion requirement in infective endocarditis patients undergoing cardiac surgery. | Korean J Anesthesiol | 2012 | https://conductscience.org/library/papers/22949982 | PubMed |
| 22534716 | Guanylate cyclase inhibition by methylene blue as an option in the treatment of vasoplegia after a severe burn. A medical hypothesis. | Med Sci Monit | 2012 | https://conductscience.org/library/papers/22534716 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/10694631
GET https://conductscience.org/api/papers/v1/10694631/authors